S
Sangeetha M. Reddy
Researcher at University of Texas MD Anderson Cancer Center
Publications - 46
Citations - 8103
Sangeetha M. Reddy is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Immunotherapy. The author has an hindex of 17, co-authored 29 publications receiving 5025 citations. Previous affiliations of Sangeetha M. Reddy include University of Texas Southwestern Medical Center & Northwestern University.
Papers
More filters
Journal ArticleDOI
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
Vancheswaran Gopalakrishnan,Vancheswaran Gopalakrishnan,Christine N. Spencer,Christine N. Spencer,Luigi Nezi,Alexandre Reuben,Miles C. Andrews,Tatiana Karpinets,Peter A. Prieto,D. Vicente,K. Hoffman,Spencer C. Wei,Alexandria P. Cogdill,Li Zhao,Courtney W. Hudgens,Diane S. Hutchinson,T. Manzo,M. Petaccia de Macedo,Tiziana Cotechini,T. Kumar,Wei Shen Chen,Sangeetha M. Reddy,R. Szczepaniak Sloane,Jessica Galloway-Peña,Hong Jiang,P. L. Chen,Elizabeth J. Shpall,Katayoun Rezvani,Amin M. Alousi,Roy F. Chemaly,Samuel A. Shelburne,Luis M Vence,Pablo C. Okhuysen,V. B. Jensen,Alton G. Swennes,Florencia McAllister,E. Marcelo Riquelme Sanchez,Yu Zhang,Laurence Zitvogel,Nicolas Pons,Jacob Austin-Breneman,Lauren E. Haydu,Elizabeth M. Burton,J. M. Gardner,E. Sirmans,Jing Shan Hu,Alexander J. Lazar,Takahiro Tsujikawa,Adi Diab,Hussein Abdul-Hassan Tawbi,Isabella C. Glitza,Wen-Jen Hwu,Sapna Pradyuman Patel,Scott E. Woodman,Rodabe N. Amaria,Michael A. Davies,Jeffrey E. Gershenwald,Patrick Hwu,J. E. Lee,Jianhua Zhang,Lisa M. Coussens,Zachary A. Cooper,P.A. Futreal,Carrie R. Daniel,Carrie R. Daniel,Nadim J. Ajami,Joseph F. Petrosino,Michael T. Tetzlaff,Pradeep Sharma,James P. Allison,Robert R. Jenq,Jennifer A. Wargo +71 more
TL;DR: Examination of the oral and gut microbiome of melanoma patients undergoing anti-programmed cell death 1 protein (PD-1) immunotherapy suggested enhanced systemic and antitumor immunity in responding patients with a favorable gut microbiome as well as in germ-free mice receiving fecal transplants from responding patients.
Journal ArticleDOI
B cells and tertiary lymphoid structures promote immunotherapy response
Beth A. Helmink,Sangeetha M. Reddy,Jianjun Gao,Shaojun Zhang,Rafet Basar,Rohit Thakur,Keren Yizhak,Moshe Sade-Feldman,Moshe Sade-Feldman,Jorge Blando,Guangchun Han,Vancheswaran Gopalakrishnan,Yuanxin Xi,Hao Zhao,Rodabe N. Amaria,Hussein Abdul-Hassan Tawbi,Alex P. Cogdill,Wenbin Liu,Valerie S. LeBleu,Fernanda G. Kugeratski,Sapna Pradyuman Patel,Michael A. Davies,Patrick Hwu,Jeffrey E. Lee,Jeffrey E. Gershenwald,Anthony Lucci,Reetakshi Arora,Scott E. Woodman,Emily Z. Keung,Pierre Olivier Gaudreau,Alexandre Reuben,Christine N. Spencer,Elizabeth M. Burton,Lauren E. Haydu,Alexander J. Lazar,Roberta Zapassodi,Courtney W. Hudgens,Deborah A. Ledesma,SuFey Ong,Michael Bailey,Sarah Warren,Disha Rao,Oscar Krijgsman,Elisa A. Rozeman,Daniel S. Peeper,Christian U. Blank,Ton N. Schumacher,Lisa H. Butterfield,Monika A. Zelazowska,Kevin M. McBride,Raghu Kalluri,James P. Allison,Florent Petitprez,Florent Petitprez,Wolf H. Fridman,Wolf H. Fridman,Catherine Sautès-Fridman,Catherine Sautès-Fridman,Nir Hacohen,Nir Hacohen,Katayoun Rezvani,Padmanee Sharma,Michael T. Tetzlaff,Linghua Wang,Jennifer A. Wargo +64 more
TL;DR: B cell markers were the most differentially expressed genes in the tumours of responders versus non-responders and insights are provided into the potential role of B cells and tertiary lymphoid structures in the response to ICB treatment, with implications for the development of biomarkers and therapeutic targets.
Journal ArticleDOI
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.
Moshe Sade-Feldman,Moshe Sade-Feldman,Keren Yizhak,Stacey L. Bjorgaard,Stacey L. Bjorgaard,John P. Ray,Carl G. de Boer,Russell W. Jenkins,David J. Lieb,Jonathan H. Chen,Jonathan H. Chen,Dennie T. Frederick,Michal Barzily-Rokni,Samuel S. Freeman,Alexandre Reuben,Paul Hoover,Paul Hoover,Alexandra-Chloé Villani,Alexandra-Chloé Villani,Elena Ivanova,Andrew Portell,Patrick H. Lizotte,Amir Reza Aref,Jean Pierre Eliane,Marc R. Hammond,Hans Vitzthum,Shauna M. Blackmon,Bo Li,Bo Li,Vancheswaran Gopalakrishnan,Sangeetha M. Reddy,Zachary A. Cooper,Cloud P. Paweletz,David A. Barbie,Anat Stemmer-Rachamimov,Keith T. Flaherty,Jennifer A. Wargo,Genevieve M. Boland,Ryan J. Sullivan,Gad Getz,Nir Hacohen,Nir Hacohen +41 more
TL;DR: The study of immune cell transcriptomes from tumors demonstrates a strategy for identifying predictors, mechanisms, and targets for enhancing checkpoint immunotherapy by targeting novel combinations of factors in exhausted cells.
Journal ArticleDOI
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Pei Ling Chen,Whijae Roh,Alexandre Reuben,Zachary A. Cooper,Christine N. Spencer,Peter A. Prieto,John P. Miller,Roland L. Bassett,Vancheswaran Gopalakrishnan,Khalida Wani,Mariana Petaccia de Macedo,Jacob Austin-Breneman,Hong Jiang,Qing Chang,Sangeetha M. Reddy,Wei Shen Chen,Michael T. Tetzlaff,Russell J. Broaddus,Michael A. Davies,Jeffrey E. Gershenwald,Lauren E. Haydu,Alexander J. Lazar,Sapna Pradyuman Patel,Patrick Hwu,Wen-Jen Hwu,Adi Diab,Isabella C. Glitza,Scott E. Woodman,Luis M Vence,Ignacio I. Wistuba,Rodabe N. Amaria,Lawrence N. Kwong,Victor G. Prieto,R. Eric Davis,Wencai Ma,Willem W. Overwijk,Arlene H. Sharpe,Jianhua Hu,P. Andrew Futreal,Jorge Blando,Padmanee Sharma,James P. Allison,Lynda Chin,Jennifer A. Wargo +43 more
TL;DR: It is demonstrated that adaptive immune signatures in tumor biopsy samples obtained early during the course of treatment are highly predictive of response to immune checkpoint blockade and also demonstrate differential effects on the tumor microenvironment induced by CTLA4 and PD-1 blockade.
Journal ArticleDOI
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
Whijae Roh,Pei Ling Chen,Alexandre Reuben,Christine N. Spencer,Peter A. Prieto,John P. Miller,Vancheswaran Gopalakrishnan,Feng Wang,Zachary A. Cooper,Sangeetha M. Reddy,Curtis Gumbs,Latasha Little,Qing Chang,Wei Shen Chen,Khalida Wani,Mariana Petaccia de Macedo,Eveline Chen,Jacob Austin-Breneman,Hong Jiang,Jason Roszik,Michael T. Tetzlaff,Michael A. Davies,Jeffrey E. Gershenwald,Hussein Abdul-Hassan Tawbi,Alexander J. Lazar,Patrick Hwu,Wen-Jen Hwu,Adi Diab,Isabella C. Glitza,Sapna Pradyuman Patel,Scott E. Woodman,Rodabe N. Amaria,Victor G. Prieto,Jianhua Hu,Padmanee Sharma,James P. Allison,Lynda Chin,Jianhua Zhang,Jennifer A. Wargo,P. Andrew Futreal +39 more
TL;DR: Deep molecular profiling of melanoma patients treated with sequential checkpoint blockade demonstrated that a more clonal T cell repertoire was predictive of response to PD-1 but not CTLA-4 blockade, suggesting the potential utility of a combinatorial biomarker to optimize patient care with checkpoint blockade therapy.